@erosolaraijs/cure 3.0.9 → 3.0.10

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (3) hide show
  1. package/dist/bin/cure.js +6 -6
  2. package/package.json +1 -1
  3. package/src/bin/cure.ts +6 -6
package/dist/bin/cure.js CHANGED
@@ -1015,15 +1015,15 @@ function getSampleTrials(cancerType) {
1015
1015
  'NSCLC': [
1016
1016
  { nctId: 'NCT04613596', title: 'Sotorasib + Pembrolizumab in KRAS G12C NSCLC', phase: 'Phase II', intervention: 'KRAS G12C inhibitor + anti-PD-1' },
1017
1017
  { nctId: 'NCT04487080', title: 'Osimertinib + Savolitinib in EGFR/MET NSCLC', phase: 'Phase III', intervention: 'EGFR TKI + MET inhibitor' },
1018
- { nctId: 'NCT03924869', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1018
+ { nctId: 'NCT03164616', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1019
1019
  ],
1020
1020
  'Lung': [
1021
1021
  { nctId: 'NCT04613596', title: 'Sotorasib + Pembrolizumab in KRAS G12C NSCLC', phase: 'Phase II', intervention: 'KRAS G12C inhibitor + anti-PD-1' },
1022
1022
  { nctId: 'NCT04487080', title: 'Osimertinib + Savolitinib in EGFR/MET NSCLC', phase: 'Phase III', intervention: 'EGFR TKI + MET inhibitor' },
1023
- { nctId: 'NCT03924869', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1023
+ { nctId: 'NCT03164616', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1024
1024
  ],
1025
1025
  'Breast': [
1026
- { nctId: 'NCT04585958', title: 'DESTINY-Breast06: T-DXd in HER2-low', phase: 'Phase III', intervention: 'Trastuzumab Deruxtecan (ADC)' },
1026
+ { nctId: 'NCT04494425', title: 'DESTINY-Breast06: T-DXd in HER2-low', phase: 'Phase III', intervention: 'Trastuzumab Deruxtecan (ADC)' },
1027
1027
  { nctId: 'NCT04191135', title: 'TROPiCS-02: Sacituzumab Govitecan', phase: 'Phase III', intervention: 'TROP2 ADC' },
1028
1028
  { nctId: 'NCT04305496', title: 'CAPItello-291: Capivasertib + Fulvestrant', phase: 'Phase III', intervention: 'AKT inhibitor combo' }
1029
1029
  ],
@@ -1045,7 +1045,7 @@ function getSampleTrials(cancerType) {
1045
1045
  'Prostate': [
1046
1046
  { nctId: 'NCT03732820', title: 'PROpel: Olaparib + Abiraterone in mCRPC', phase: 'Phase III', intervention: 'PARP + androgen inhibitor' },
1047
1047
  { nctId: 'NCT03834519', title: 'TALAPRO-2: Talazoparib + Enzalutamide', phase: 'Phase III', intervention: 'PARP + AR inhibitor' },
1048
- { nctId: 'NCT03395197', title: 'VISION: Lu-177-PSMA-617 in mCRPC', phase: 'Phase III', intervention: 'Radioligand therapy' }
1048
+ { nctId: 'NCT03511664', title: 'VISION: Lu-177-PSMA-617 in mCRPC', phase: 'Phase III', intervention: 'Radioligand therapy' }
1049
1049
  ],
1050
1050
  'Kidney': [
1051
1051
  { nctId: 'NCT04523272', title: 'LITESPARK-005: Belzutifan vs Everolimus', phase: 'Phase III', intervention: 'HIF-2α inhibitor' },
@@ -1068,7 +1068,7 @@ function getSampleTrials(cancerType) {
1068
1068
  { nctId: 'NCT04150029', title: 'Magrolimab + Azacitidine in AML', phase: 'Phase III', intervention: 'CD47 + HMA' }
1069
1069
  ],
1070
1070
  'Lymphoma': [
1071
- { nctId: 'NCT03761056', title: 'ZUMA-7: Axi-cel vs SOC in LBCL', phase: 'Phase III', intervention: 'CAR-T cell therapy' },
1071
+ { nctId: 'NCT03391466', title: 'ZUMA-7: Axi-cel vs SOC in LBCL', phase: 'Phase III', intervention: 'CAR-T cell therapy' },
1072
1072
  { nctId: 'NCT04002401', title: 'Glofitamab + Gemcitabine + Oxaliplatin', phase: 'Phase III', intervention: 'CD20xCD3 bispecific' },
1073
1073
  { nctId: 'NCT03331198', title: 'TRANSFORM: Liso-cel vs SOC', phase: 'Phase III', intervention: 'CAR-T second line' }
1074
1074
  ],
@@ -1093,7 +1093,7 @@ function getSampleTrials(cancerType) {
1093
1093
  // Return cancer-specific trials if available, otherwise return pan-tumor trials
1094
1094
  return trials[cancerKey] || [
1095
1095
  { nctId: 'NCT02628067', title: 'KEYNOTE-158: Pembrolizumab in MSI-H/dMMR Tumors', phase: 'Phase II', intervention: 'Anti-PD-1 (tumor-agnostic)' },
1096
- { nctId: 'NCT02576431', title: 'NCI-MATCH: Targeted Therapy by Mutation', phase: 'Phase II', intervention: 'Biomarker-matched therapy' },
1096
+ { nctId: 'NCT02465060', title: 'NCI-MATCH: Targeted Therapy by Mutation', phase: 'Phase II', intervention: 'Biomarker-matched therapy' },
1097
1097
  { nctId: 'NCT02693535', title: 'TAPUR: Targeted Agents for Rare Mutations', phase: 'Phase II', intervention: 'Precision oncology basket' }
1098
1098
  ];
1099
1099
  }
package/package.json CHANGED
@@ -1,6 +1,6 @@
1
1
  {
2
2
  "name": "@erosolaraijs/cure",
3
- "version": "3.0.9",
3
+ "version": "3.0.10",
4
4
  "description": "AI-powered unified cancer treatment framework with multi-provider support for medical research and patient care",
5
5
  "main": "dist/bin/cure.js",
6
6
  "type": "module",
package/src/bin/cure.ts CHANGED
@@ -1135,15 +1135,15 @@ function getSampleTrials(cancerType: string): Array<{nctId: string, title: strin
1135
1135
  'NSCLC': [
1136
1136
  { nctId: 'NCT04613596', title: 'Sotorasib + Pembrolizumab in KRAS G12C NSCLC', phase: 'Phase II', intervention: 'KRAS G12C inhibitor + anti-PD-1' },
1137
1137
  { nctId: 'NCT04487080', title: 'Osimertinib + Savolitinib in EGFR/MET NSCLC', phase: 'Phase III', intervention: 'EGFR TKI + MET inhibitor' },
1138
- { nctId: 'NCT03924869', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1138
+ { nctId: 'NCT03164616', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1139
1139
  ],
1140
1140
  'Lung': [
1141
1141
  { nctId: 'NCT04613596', title: 'Sotorasib + Pembrolizumab in KRAS G12C NSCLC', phase: 'Phase II', intervention: 'KRAS G12C inhibitor + anti-PD-1' },
1142
1142
  { nctId: 'NCT04487080', title: 'Osimertinib + Savolitinib in EGFR/MET NSCLC', phase: 'Phase III', intervention: 'EGFR TKI + MET inhibitor' },
1143
- { nctId: 'NCT03924869', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1143
+ { nctId: 'NCT03164616', title: 'POSEIDON: Durvalumab + Tremelimumab', phase: 'Phase III', intervention: 'PD-L1/CTLA-4 + chemo' }
1144
1144
  ],
1145
1145
  'Breast': [
1146
- { nctId: 'NCT04585958', title: 'DESTINY-Breast06: T-DXd in HER2-low', phase: 'Phase III', intervention: 'Trastuzumab Deruxtecan (ADC)' },
1146
+ { nctId: 'NCT04494425', title: 'DESTINY-Breast06: T-DXd in HER2-low', phase: 'Phase III', intervention: 'Trastuzumab Deruxtecan (ADC)' },
1147
1147
  { nctId: 'NCT04191135', title: 'TROPiCS-02: Sacituzumab Govitecan', phase: 'Phase III', intervention: 'TROP2 ADC' },
1148
1148
  { nctId: 'NCT04305496', title: 'CAPItello-291: Capivasertib + Fulvestrant', phase: 'Phase III', intervention: 'AKT inhibitor combo' }
1149
1149
  ],
@@ -1165,7 +1165,7 @@ function getSampleTrials(cancerType: string): Array<{nctId: string, title: strin
1165
1165
  'Prostate': [
1166
1166
  { nctId: 'NCT03732820', title: 'PROpel: Olaparib + Abiraterone in mCRPC', phase: 'Phase III', intervention: 'PARP + androgen inhibitor' },
1167
1167
  { nctId: 'NCT03834519', title: 'TALAPRO-2: Talazoparib + Enzalutamide', phase: 'Phase III', intervention: 'PARP + AR inhibitor' },
1168
- { nctId: 'NCT03395197', title: 'VISION: Lu-177-PSMA-617 in mCRPC', phase: 'Phase III', intervention: 'Radioligand therapy' }
1168
+ { nctId: 'NCT03511664', title: 'VISION: Lu-177-PSMA-617 in mCRPC', phase: 'Phase III', intervention: 'Radioligand therapy' }
1169
1169
  ],
1170
1170
  'Kidney': [
1171
1171
  { nctId: 'NCT04523272', title: 'LITESPARK-005: Belzutifan vs Everolimus', phase: 'Phase III', intervention: 'HIF-2α inhibitor' },
@@ -1188,7 +1188,7 @@ function getSampleTrials(cancerType: string): Array<{nctId: string, title: strin
1188
1188
  { nctId: 'NCT04150029', title: 'Magrolimab + Azacitidine in AML', phase: 'Phase III', intervention: 'CD47 + HMA' }
1189
1189
  ],
1190
1190
  'Lymphoma': [
1191
- { nctId: 'NCT03761056', title: 'ZUMA-7: Axi-cel vs SOC in LBCL', phase: 'Phase III', intervention: 'CAR-T cell therapy' },
1191
+ { nctId: 'NCT03391466', title: 'ZUMA-7: Axi-cel vs SOC in LBCL', phase: 'Phase III', intervention: 'CAR-T cell therapy' },
1192
1192
  { nctId: 'NCT04002401', title: 'Glofitamab + Gemcitabine + Oxaliplatin', phase: 'Phase III', intervention: 'CD20xCD3 bispecific' },
1193
1193
  { nctId: 'NCT03331198', title: 'TRANSFORM: Liso-cel vs SOC', phase: 'Phase III', intervention: 'CAR-T second line' }
1194
1194
  ],
@@ -1215,7 +1215,7 @@ function getSampleTrials(cancerType: string): Array<{nctId: string, title: strin
1215
1215
  // Return cancer-specific trials if available, otherwise return pan-tumor trials
1216
1216
  return trials[cancerKey] || [
1217
1217
  { nctId: 'NCT02628067', title: 'KEYNOTE-158: Pembrolizumab in MSI-H/dMMR Tumors', phase: 'Phase II', intervention: 'Anti-PD-1 (tumor-agnostic)' },
1218
- { nctId: 'NCT02576431', title: 'NCI-MATCH: Targeted Therapy by Mutation', phase: 'Phase II', intervention: 'Biomarker-matched therapy' },
1218
+ { nctId: 'NCT02465060', title: 'NCI-MATCH: Targeted Therapy by Mutation', phase: 'Phase II', intervention: 'Biomarker-matched therapy' },
1219
1219
  { nctId: 'NCT02693535', title: 'TAPUR: Targeted Agents for Rare Mutations', phase: 'Phase II', intervention: 'Precision oncology basket' }
1220
1220
  ];
1221
1221
  }